Vetoquinol SA (VETO.PA)
- Previous Close
94.50 - Open
94.60 - Bid --
- Ask --
- Day's Range
94.50 - 95.70 - 52 Week Range
76.30 - 110.00 - Volume
375 - Avg. Volume
3,296 - Market Cap (intraday)
1.133B - Beta (5Y Monthly) 0.91
- PE Ratio (TTM)
19.26 - EPS (TTM)
4.97 - Earnings Date Mar 20, 2024
- Forward Dividend & Yield 0.80 (0.85%)
- Ex-Dividend Date Jun 2, 2023
- 1y Target Est
109.10
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
www.vetoquinol.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: VETO.PA
Performance Overview: VETO.PA
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VETO.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VETO.PA
Valuation Measures
Market Cap
1.12B
Enterprise Value
1.03B
Trailing P/E
19.01
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.13
Price/Book (mrq)
2.21
Enterprise Value/Revenue
1.97
Enterprise Value/EBITDA
9.14
Financial Highlights
Profitability and Income Statement
Profit Margin
10.50%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
529.3M
Net Income Avi to Common (ttm)
55.6M
Diluted EPS (ttm)
4.97
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--